Abstract Number: PB0027
Meeting: ISTH 2021 Congress
Background: Dialysis-dependent patients with end-stage renal disease (ESRD) commonly present with a variety of comorbidities, including an increased risk of cardiovascular disease. Biomarkers such as, tPA, D-dimer, and nitrotyrosine can serve as predictive factors for the estimation of vascular condition in patients with ESRD. Atrial fibrillation (AFIB) and peripheral arterial disease (PAD), can alter these biomarkers adversely affecting the health of the patients.
Aims: The objective of this study was to firstly establish a profile of the aforementioned biomarkers in patients with ESRD, ESRD and atrial fibrillation, as well as ESRD and PAD; and secondly, compare how these biomarkers and lab parameters have changed in patients who have cardiovascular comorbidities in addition to ESRD.
Methods: Blood samples were drawn from 95 patients with ESRD enrolled from Loyola Medical Center under the approved IRB protocol (#LU107346). The biomarker levels were measured from citrated plasma levels of these samples using commercially available enzyme linked immune-absorbent assays (ELISAs). Lab parameters and patient comorbidities were obtained through a review of the patient medical records. The comorbidities were determined through provider notes, and evidence of applicable testing.
Results: Of the 94 patients with ESRD, 14.89% of patients were found to have atrial fibrillation (n=14), 30.85% of patients were found to have peripheral arterial disease (n=29), and 6.38% of patients were found to have both peripheral arterial disease and atrial fibrillation (n=6). When compared to patients with only ESRD, patients with ESRD and PAD showed elevated levels of D-Dimer (p = .0314) and nitrotyrosine (p = .0330). When compared to patients with only ESRD, patients with atrial fibrillation showed elevated levels of D-Dimer (p=.0372), nitrotyrosine (p=.0322), and tPA (p=.0198).
Conclusions: Atrial fibrillation and PAD is frequently encountered in patients with ESRD. Nitrotyrosine and d-dimer levels are elevated in patients with ESRD and concomitant PAD or atrial fibrillation.
To cite this abstract in AMA style:Goldstein J, Dieter R, Wieschhaus K, Fareed J. Changes in Vascular Physiology in Patients with End Stage Renal Disease Compared to Patients with ESRD and Concomitant Cardiovascular Disease [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/changes-in-vascular-physiology-in-patients-with-end-stage-renal-disease-compared-to-patients-with-esrd-and-concomitant-cardiovascular-disease/. Accessed May 19, 2022.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/changes-in-vascular-physiology-in-patients-with-end-stage-renal-disease-compared-to-patients-with-esrd-and-concomitant-cardiovascular-disease/